The present invention relates to methods and systems for optimization of dilution of a viscous starting material to isolate and/or concentrate the product of interest from the starting source material such that the process minimizes the volume of diluent and the total volume of the waste stream generated during the process as well as maximizing the yield of desired product. The system employs cross-flow filtration modules with sub-channels that are equidistant to the inlet and outlet of said modules and such modules are characterized by optimal channel height, optimal transmembrane pressure, etc., which are selected in order to achieve the best combination of product quality and production yield.

Disclosed herein is a single pass cross flow diafiltration system comprising: a filtration module having; two or more filtration segments fluidly connected in series, each having an upstream side and a downstream side; wherein each filtration segment comprises hollow fiber filter membranes, and wherein each filtration segment has a selected length; wherein the hollow fiber filter membranes of each filtration segment have a selected inner diameter; wherein the selected inner diameter of each filtration segment may be the same or different, provided that at least one selected inner diameter differs from another selected inner diameter, and provided that the two or more filtration segments are arranged such that no selected inner diameter in a given filtration segment is larger on the upstream side; one or more pumps, mounted to urge fluid flow; and one or more points of introduction of a diadiluent, each of said points of introduction being fluidly connected to an upstream filtration segment.

Embodiments of the present application relate to compositions bupivacaine multivesicular liposomes (MVLs) prepared by a commercial manufacturing process with large particle diameter span.

A diafiltration system comprises a fluid treatment assembly comprising two or more fluid treatment modules, the fluid treatment assembly comprising a feed inlet, a permeate outlet, and a retentate outlet; each module comprising a cross flow treatment assembly including an ultrafiltration membrane and having a feed side and a permeate side, and a diafiltration fluid distribution plate comprising a diafiltration fluid feed inlet and a common feed permeate/diafiltration fluid permeate outlet port; two or more diafiltration fluid conduits, each conduit in fluid communication with a respective single diafiltration fluid feed inlet; and, a diafiltration fluid pump comprising at least a first multiple channel pump head having at least two channels including separate channels for separate conduits in fluid communication with respective single diafiltration fluid feed inlets, wherein the pump provides simultaneously controlled diafiltration fluid flow rates through each of the conduits to the respective diafiltration fluid feed inlets.

A technology that provides various modular biomimetic microfluidic modules emulating varieties of microvasculature in body. These microfluidic-base capillaries and lymphatic Technology modules are constructed as multilayered-microfluidic microchannels of various shapes, and aspect ratios using diverse biocompatible microfluidic polymers. Then, various semipermeable membranes are sandwiched in between these multilayered microfluidic microchannels. These membranes have different chemical, physical characteristics and MWCO values. Consequently, this design will produce much smaller dimension channels similar to human vasculature to achieve biomimetic properties like of human organs and tissues. By interchanging microfluidic-layers or the membranes various diverse modules are designed that act as building blocks for constructing various medical devices, various forms of dialysis devices including albumin and lipid dialysis, water purification, bioreactors, bio-artificial organ support systems. Connecting various modules in diverse combinations, permutations, in parallel and/or in series to ultimately design many unrelated medical devices such as dialysis, bioreactors and organ support devices.

Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

Apparatus, methods, systems, etc., for the tangential flow filtration (TFF) of viscous compositions including viscous fluids, solutions, gels, pastes, creams and suspensions with viscosities greater than 10 cP, 20 cP, 50 cP or 100 cP. The methods, etc., provide enhanced mixing of the viscous compositions in their storage vessels by extracting the input composition from different depths in the storage vessels to reduce or eliminate vertical concentration gradients.

The method for producing a phospholipid concentrate derived from a liquid dairy composition comprising at least caseins and phospholipids, includes at least the steps of: —passing the dairy composition into an ion-exchange column on a cationic resin, —concentrating the phospholipids of the calcium-depleted dairy composition by means of controlled transmembrane pressure gradient microfiltration, and —recovering the retentate from the microfiltration and obtaining a phospholipid concentrate.

A process is described for the purification of HA, and pharmaceutical, cosmetic and nutritional compositions containing HA thus purified.

The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method comprises only filtration and precipitation steps, omitting the need for chromatography steps.